In 2016, a study I co-authored was ranked amongst the most cited papers in BiologicalPsychiatry showing that cognitive improvements in EPO-treated patients with mood disorders involves increased hippocampal volume. We have now written a Review paper about EPO, cognition, depression and its underlying molecular mechanisms centred around GSK3beta. The manuscript is currently under review with Translational Psychiatry.

More information coming soon!

In the meantime, please feel free to continue browsing my site, or contact me for more information.